Introduction
ReDuNing is an herbal injection, which was approved in 2005 by the China Food and Drug Administration (China FDA) for treatment of viral upper respiratory tract infection associated with high fever, chills, headache, myalgia, and cough with phlegm. Each milliliter of the injection is prepared from a combination of 0.60 g of Gardenia jasminoides fruits (Zhizi), 0.75 g of Lonicera japonica flower buds (Jinyinhua), and 1.25 g of Artemisia annua aerial part (Qinghao), yielding an herb-to-injection ratio of 2.6:1. The injection is available as a sterile and nonpyrogenic dosage form for intravenous administration at a dose of 20 ml once daily for three days. ReDuNing therapy appears to have low incidence of side effects (Xu et al., 2009) . Recently, ReDuNing injection is also used as an add-on therapy in conventional treatment of hand, foot, and mouth disease in children infected with coxsackievirus type A16 or enterovirus type 71 (Li et al., 2014) . Despite its extensive use in clinics, little is known about the chemical basis responsible for the therapeutic action of ReDuNing injection.
Pharmacologically active constituents existing in adequate abundance in an herbal medicine and exhibiting favorable pharmacokinetic profiles are most likely to form the chemical basis responsible for the medicine's therapeutic action. ReDuNing injection has been reported to contain iridoids, organic acids, and flavonoids (Li et al., 2015a) . These compounds are important because of their reported antiviral, anti-inflammatory, and antioxidative properties as pure isolates (Shang et al., 2011; Liu et al., 2013) . Although bioanalytical assays were developed for measurement of concentrations of some iridoids and organic acids in human and rat plasma after dosing ReDuNing injection (Ni et al., 2015; Wang et al., 2015) , pharmacokinetic information about ReDuNing injection is still limited. This hinders understanding the This article has not been copyedited and formatted. The final version may differ from this version. -5 -chemical basis responsible for the therapeutic action of ReDuNing injection. The current study was designed to assess systemic exposure to ReDuNing compounds in rats intravenously receiving the herbal injection and to investigate pharmacokinetics and elimination of the major circulating herbal compounds.
Materials and Methods

A detailed description of materials and methods is provided in Supplemental
Materials and Methods, which are available online. -6 - (Reagan-Shaw et al., 2008) . In the first rat study, blood samples (~80 μ l) were collected from four rats, into heparinized tubes, before and 0. 083, 0.25, 0.5, 0.58, 0.75, 1, 1.5, 2.5, 4.5, 6.5, 8.5 , and 24 hours after starting infusion; the plasma fractions were prepared by centrifuging the blood samples. In the second rat study, urine samples were collected, from four rats, before and 0-4, 4-8, and 8-24 hours after starting infusion. In the third rat study, bile samples were collected, from four rats, before and 0-2, 2-4, 4-6, 6-8, and 8-24 hours after starting infusion.
ReDuNing Injection and Its
In Vitro Metabolism Studies. To characterize metabolism of herbal compounds in rats and to facilitate prediction of the metabolism in humans, metabolic capacities of cytochrome P450 (P450), carbonyl reductase (CR), catechol-O-methyltransferase (COMT), UDP-glucuronosyltransferase (UGT), and sulfotransferase (SULT) for
ReDuNing compounds were assessed using rat liver microsomes and cytosol, as well as human liver microsomes and cytosol. The preceding metabolic reactions were repeated by adding glutathione (GSH) into the incubations. Also, interplays of COMT with UGT and with SULT were also evaluated using methods by Li et al. (2015b) .
Determination of Plasma Protein Binding.
Fractions of unbound compounds to rat plasma proteins (f u ) were assessed by an ultrafiltration method (Guo et al., 2006 -7 -Philadelphia, PA). All data are expressed as the mean ± standard deviation.
Results and Discussion
Analysis of the chemical composition of ReDuNing injection was the first step in pharmacokinetic research on the injection. The aims of the analysis were to understand which, and how much, herbal compounds were introduced into the bloodstream by dosing the injection and to understand the injection's lot-to-lot variability. A total of 46 compounds (19 iridoids, 16 organic acids, and 11 flavonoids)
were detected in ReDuNing injection (Fig. 1) . The compounds could be graded according to their dose levels from ReDuNing injection at the label daily dose 20 ml/person. The iridoids geniposide (6) and secologanic acid (4) and the organic acids chlorogenic acid (30), quinic acid (25), cryptochlorogenic acid (31), and neochlorogenic acid (29) exhibited dose levels of >100 μ mol/person (135-592 μ mol/person); the injection exhibited small lot-to-lot variability (3.1-7.9%) for these compounds, except for 4 being 26.4% (Supplemental Table 1 ). The sum of the dose levels of 6 and 4 was 78.2% of the total dose of iridoids present in ReDuNing injection, whereas the sum of the dose levels of 30, 25, 31, and 29 was 89.6% of the total dose of organic acids in the injection. The dose levels of secoxyloganin (12) were detected in plasma samples of rats after starting infusion. The iridoids geniposide (6), secologanic acid (4), secoxyloganin (12), and geniposidic acid (3) and the organic acids chlorogenic acid (30), quinic acid (25), cryptochlorogenic acid (31), and neochlorogenic acid (29) exhibited high levels of systemic exposure; whereas the iridoids sweroside (2), genipin-1-β-gentiobioside (16), and shanzhiside (9) were at lower levels. Chemical structures of these major circulating ReDuNing compounds are shown in Fig. 2 . The plasma flavonoids detected were at quite low levels. A total of 40 unchanged ReDuNing compounds were detected in rat urine samples, whereas only 24 such compounds were detected, all at low levels, in bile samples (Fig. 2 ).
Renal excretion of unchanged compound was found to be the main elimination pathway for the major circulating iridoids 6, 12, 16, 2, and 9 with fractions of doses excreted into urine (f e-U ) of 64.0-87.5%, whereas the f e-U of the iridoid 3 was 334.8%.
As shown in Supplemental Table 2B , an in vitro metabolism study using rat liver microsomes suggested that P450-mediated and NADPH-dependent oxidative ester cleavage of 6 probably took place in rats to yield 3. Unlike for these iridoids, renal -9 -excretion was a minor elimination pathway for the iridoid 4 (f e-U , 7.3%); so was biliary excretion (fraction of dose excreted into bile, f e-B ; 0.1%). A reduced metabolite of 4 (M4 R ) was detected in rat plasma, urine, and bile samples (Supplemental Fig. 1 and Supplemental Table 2A ); the metabolism was probably mediated by carbonyl reductase (CR) in rat liver cytosol fortified with NADPH (Supplemental Table 2B) and could be inhibited by quercetin. The organic acid 25 was also primarily eliminated unchanged via renal excretion (f e-U , 89.7%). The f e-U values of the other organic acids 30, 31, and 29 (31.9-44.2%) were lower than that of 25; several metabolites of these compounds were detected in rats (Supplemental Fig. 1 and Supplemental Table 2A ). Because 30, 31, and 29 were isomers with the same molecular mass 354 daltons, characterization of the parent compound and metabolite relationship was achieved by in vitro metabolism study using purified compounds as substrates (Supplemental Table 2B ). As a result, the detected plasma metabolites were Figure   3 shows proposed metabolic pathways of 6, 4, 30, 31, and 29 in rats intravenously receiving ReDuNing injection. In vitro metabolism studies using human liver microsomes and cytosol suggested that the preceding metabolism of 6, 4, 30, 31, and 29 in rats probably also occurred in humans (Supplemental Table 2B ). -10 -the 30-minute infusion was continued with the maximum plasma concentrations (C max )
being measured just prior to completion of the infusions (Supplemental Fig. 2 ). The
ReDuNing compounds exhibited short elimination half-lives (t 1/2 ), i.e. 0.3-0.9 hour for the iridoids geniposide (6), secologanic acid (4), secoxyloganin (12), genipin-1-β-gentiobioside (16), geniposidic acid (3), sweroside (2), and shanzhiside (9) and 0.2-0.5 hour for the organic acids chlorogenic acid (30), quinic acid (25) This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 1E ). See Supplemental Table 1 for the compounds'
names. The symbol "×" (in red) denotes that the compound was not detected. 
Compound ID Geniposide (6) Secologanic acid (4) Secoxyloganin (12) Genipin-1-β-gentiobioside (16) Geniposidic acid (3) Sweroside (2) Shanzhiside (9) Chlorogenic acid (30) 
Compound ID Geniposide (6) Secologanic acid (4) Secoxyloganin (12) Genipin-1-β-gentiobioside (16) Geniposidic acid (3) Sweroside (2) Shanzhiside (9) Chlorogenic acid (30) Quinic acid (25) Cryptochlorogenic acid (31) Neochlorogenic acid (29) 
